Bharat Biotech’s Covaxin demonstrates 77.8 pc efficacy in Phase III trials, say sources
Team Udayavani, Jun 22, 2021, 5:52 PM IST
New Delhi: Bharat Biotech’s Covaxin has demonstrated 77.8 per cent efficacy Phase III trials data approved by the Central Drugs Standard Control Organisation, according to sources.
The company had submitted data from the Phase III clinical trials of Covaxin to the Drugs Controller General of India (DCGI) over the weekend. Bharat Biotech’s ‘pre-submission’ meeting with the World Health Organization (WHO) will take on Wednesday for the approval for Covaxin.
The Phase III trials data findings come shortly after two studies indicated that Covaxin produces fewer antibodies than Covishield.
Covaxin is one of the three vaccines which are currently being used in India.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
2 detained under PSA, PIT-NDPS Act in J&K’s Samba, Jammu
PM Modi calls Gukesh an embodiment of calmness and humility
Delhi Police announces traffic arrangements for New Year eve celebrations
Case lodged against unknown person for issuing threats to Sambhal MP
Nigambodh Ghat: Delhi’s oldest, busiest crematorium and a bird watcher’s paradise
MUST WATCH
Latest Additions
2 detained under PSA, PIT-NDPS Act in J&K’s Samba, Jammu
PM Modi calls Gukesh an embodiment of calmness and humility
Delhi Police announces traffic arrangements for New Year eve celebrations
Case lodged against unknown person for issuing threats to Sambhal MP
Priyank Kharge favours independent probe into Bidar contractor’s ‘suicide’, rejects BJP’s demand
Thanks for visiting Udayavani
You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.